FOXO3a and the MAPK p38 are activated by cetuximab to induce cell death and inhibit cell proliferation and their expression predicts cetuximab efficacy in colorectal cancer. (2016)
Attributed to:
Targeting the FOXM1 signature for early diagnosis and treatment in cholangiocarcinoma
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1038/bjc.2016.313
PubMed Identifier: 27685445
Publication URI: http://europepmc.org/abstract/MED/27685445
Type: Journal Article/Review
Volume: 115
Parent Publication: British journal of cancer
Issue: 10
ISSN: 0007-0920